

# Indian Journal of Dermatology, Venereology & Leprology

Journal indexed with SCI-E, PubMed, and EMBASE

Vol 74 | Issue 2 | Mar-Apr 2008

C O N T E N T S

## EDITORIAL

### Management of autoimmune urticaria

Arun C. Inamadar, Aparna Palit ..... 89

## VIEW POINT

### Cosmetic dermatology versus cosmetology: A misnomer in need of urgent correction

Shyam B. Verma, Zoe D. Draelos ..... 92

## REVIEW ARTICLE

### Psoriasiform dermatoses

Virendra N. Sehgal, Sunil Dogra, Govind Srivastava, Ashok K. Aggarwal ..... 94



## ORIGINAL ARTICLES

### A study of allergen-specific IgE antibodies in Indian patients of atopic dermatitis

V. K. Somani ..... 100

### Chronic idiopathic urticaria: Comparison of clinical features with positive autologous serum skin test

George Mamatha, C. Balachandran, Prabhu Smitha ..... 105



### Autologous serum therapy in chronic urticaria: Old wine in a new bottle

A. K. Bajaj, Abir Saraswat, Amitabh Upadhyay, Rajetha Damisetty, Sandipan Dhar ..... 109

### Use of patch testing for identifying allergen causing chronic urticaria

Ashimav Deb Sharma ..... 114

### Vitiligoid lichen sclerosus: A reappraisal

Venkat Ratnam Attali, Sasi Kiran Attali ..... 118



**BRIEF REPORTS**

**Activated charcoal and baking soda to reduce odor associated with extensive blistering disorders**

Arun Chakravarthi, C. R. Srinivas, Anil C. Mathew ..... 122



**Nevus of Ota: A series of 15 cases**

Shanmuga Sekar, Maria Kuruvila, Harsha S. Pai ..... 125



**Premature ovarian failure due to cyclophosphamide: A report of four cases in dermatology practice**

Vikrant A. Saoji ..... 128

**CASE REPORTS**

**Hand, foot and mouth disease in Nagpur**

Vikrant A. Saoji ..... 133



**Non-familial multiple keratoacanthomas in a 70 year-old long-term non-progressor HIV-seropositive man**

Hemanta Kumar Kar, Sunil T. Sabhnani, R. K. Gautam, P. K. Sharma, Kalpana Solanki, Meenakshi Bhardwaj ..... 136



**Late onset isotretinoin resistant acne conglobata in a patient with acromegaly**

Kapil Jain, V. K. Jain, Kamal Aggarwal, Anu Bansal ..... 139



**Familial dyskeratotic comedones**

M. Sendhil Kumaran, Divya Appachu, Elizabeth Jayaseelan ..... 142



**Nasal NK/T cell lymphoma presenting as a lethal midline granuloma**

Vandana Mehta, C. Balachandran, Sudha Bhat, V. Geetha, Donald Fernandes .....



145

**Childhood sclerodermatomyositis with generalized morphea**

Girishkumar R. Ambade, Rachita S. Dhurat, Nitin Lade, Hemangi R. Jerajani.....



148

**Subcutaneous panniculitis-like T-cell cutaneous lymphoma**

Avninder Singh, Joginder Kumar, Sujala Kapur, V. Ramesh.....



151

**LETTERS TO EDITOR**

**Using a submersible pump to clean large areas of the body with antiseptics**

C. R. Srinivas .....



154

**Peutz-Jeghers syndrome with prominent palmoplantar pigmentation**


K. N. Shivaswamy, A. L. Shyamprasad, T. K. Sumathi, C. Ranganathan .....



154

**Stratum corneum findings as clues to histological diagnosis of pityriasis lichenoides chronica**

Rajiv Joshi .....



156

**Author's reply**

S. Pradeep Nair .....

157

**Omalizumab in severe chronic urticaria**

K. V. Godse.....

157

**Hypothesis: The potential utility of topical eflornithine against cutaneous leishmaniasis**

M. R. Namazi .....

158

**Nodular melanoma in a skin graft site scar**

A. Gnaneshwar Rao, Kamal K. Jhamnani, Chandana Konda .....



159

**Palatal involvement in lepromatous leprosy**

A. Gnaneshwar Rao, Chandana Konda, Kamal Jhamnani.....



161

**Unilateral nevoid telangiectasia with no estrogen and progesterone receptors in a pediatric patient**

F. Sule Afsar, Ragip Ortac, Gulden Diniz.....



163

**Eruptive lichen planus in a child with celiac disease**

Dipankar De, Amrinder J. Kanwar.....



164

**Xerosis and pityriasis alba-like changes associated with zonisamide**

Feroze Kaliyadan, Jayasree Manoj, S. Venkitakrishnan.....

165

**Treatment of actinomycetoma with combination of rifampicin and co-trimoxazole**

Rajiv Joshi.....



166

**Author's reply**

M. Ramam, Radhakrishna Bhat, Taru Garg, Vinod K. Sharma, R. Ray, M. K. Singh, U. Banerjee, C. Rajendran.....

168

**Vitiligo, psoriasis and imiquimod: Fitting all into the same pathway**

Bell Raj Eapen.....

169

**Author's reply**

Engin Şenel, Deniz Seçkin.....

169

**Multiple dermatofibromas on face treated with carbon dioxide laser: The importance of laser parameters**

Kabir Sardana, Vijay K. Garg.....

170

**Author's reply**

D. S. Krupa Shankar, A. Kushalappa, K. S. Uma, Anjay A. Pai.....

170

**Alopecia areata progressing to totalis/universalis in non-insulin dependent diabetes mellitus (type II): Failure of dexamethasone-cyclophosphamide pulse therapy**

Virendra N. Sehgal, Sambit N. Bhattacharya, Sonal Sharma, Govind Srivastava, Ashok K. Aggarwal.....



171

**Subungual exostosis**

Kamal Aggarwal, Sanjeev Gupta, Vijay Kumar Jain, Amit Mital, Sunita Gupta.....

173

**Clinicohistopathological correlation of leprosy**

Amrish N. Pandya, Hemali J. Tailor ..... 174

**RESIDENT'S PAGE**

**Dermatographism**

Dipti Bhute, Bhavana Doshi, Sushil Pande, Sunanda Mahajan, Vidya Kharkar ..... 177

**FOCUS**

**Mycophenolate mofetil**

Amar Surjushe, D. G. Saple ..... 180

**QUIZ**

**Multiple papules on the vulva**

G. Raghu Rama Rao, R. Radha Rani, A. Amareswar, P. V. Krishnam  
Raju, P. Raja Kumari, Y. Hari Kishan Kumar ..... 185



**E-IDVL**

**Net Study**

**Oral isotretinoin is as effective as a combination of oral isotretinoin and topical anti-acne agents in nodulocystic acne**

Rajeev Dhir, Neetu P. Gehi, Reetu Agarwal, Yuvraj E. More ..... 187

**Net Case**

**Cutaneous diphtheria masquerading as a sexually transmitted disease**

T. P. Vetrichevvel, Gajanan A. Pise, Kishan Kumar Agrawal,  
Devinder Mohan Thappa..... 187



**Net Letters**

**Patch test in Behcet's disease**

Ülker Gül, Müzeyyen Gönül, Seray Külcü Çakmak, Arzu Kılıç ..... 187

**Cerebriform elephantiasis of the vulva following tuberculous lymphadenitis**

Surajit Nayak, Basanti Acharjya, Basanti Devi, Satyadarshi Pattnaik,  
Manoj Kumar Patra ..... 188



**Net Quiz**

**Vesicles on the tongue**

Saurabh Agarwal, Krishna Gopal, Binay Kumar ..... 188



## Psoriasiform dermatoses

Virendra N. Sehgal, Sunil Dogra<sup>1</sup>, Govind Srivastava<sup>2</sup>, Ashok K. Aggarwal

Dermato-Venereology (Skin/VD) Centre, Sehgal Nursing Home, Panchwati, Azadpur, New Delhi, <sup>1</sup>Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, <sup>2</sup>Skin institute and School of Dermatology, Greater Kailash, New Delhi, India

**Address for correspondence:** Dr. Virendra N. Sehgal, A/6, Panchwati, New Delhi - 110 033, India. E-mail: drsehgal@ndf.vsnl.net.in

---

### ABSTRACT

Psoriasiform reaction pattern is a commonly encountered denominator in a wide variety of unrelated disorders. It may be a reaction to either the internal or the external environmental, allergic, infective, parasitic, bacterial, fungal, viral and/or malignant stimuli. The degree of evolution of such a pattern and its significance vary according to the dermatosis. The age of the skin lesions may also influence the histopathological presentation and its clinico-histopathological disparity can often bewilder an expert. However, such a situation warrants more astute and sustained observations to unveil the exact underlying condition(s). Thus, psoriasiform dermatoses should only be an initial caption until an exact dermatological disorder is defined. There has been greater number of instances of psoriasiform drug eruptions where a confirmation of the diagnosis can be achieved after their remission by doing a provocation test. Similarly, such instances have also been on the rise in HIV/AIDS-affected individuals all over the world. Besides mycosis fungoides and Hodgkin's disease, several unrelated malignancies have been preceded or accompanied by psoriasiform skin eruptions.

**Key Words:** Classification, Etiology, Pathogenesis, Psoriasiform dermatoses

### INTRODUCTION

Psoriasiform dermatoses refers to a group of disorders, which clinically and/or histologically, simulates psoriasis.<sup>[1,2]</sup> They include several unrelated disorders of the integument, which either in the beginning or in the course of progression/resolution, exhibit lesions resembling psoriasis.<sup>[3-4]</sup> Psoriasiform eruptions can commonly be seen in seborrheic dermatitis, pityriasis rubra pilaris, psoriasiform syphilids of secondary syphilis, pityriasis rosea, mycosis fungoides and drug eruptions. However, their inventory is quite exhaustive, especially when the histopathological assessment is also included to conform to the caption of psoriasiform dermatoses. Histopathologically, the psoriasiform reaction pattern is defined as the presence of epidermal hyperplasia with elongation of rete ridges in a regular manner. This definition encompasses a heterogeneous group of dermatological conditions. The morphological concept as outlined by Pinkus and Mehregan, is much broader than the pathogenetic one.<sup>[5]</sup> They considered the principle features

of the psoriasiform tissue reaction to be the formation of suprapapillary exudates with parakeratosis, secondary to intermittent release of serum and leukocytes from dilated blood vessels in the papillary dermis (the so-called squirting papilla). Psoriasis is the prototype of a psoriasiform reaction pattern.<sup>[6]</sup> The current overview attempts to clarify this commonly encountered dermatologic presentation.

### HISTORY

Psoriasis is the oldest of all recorded dermatologic disorders and hence, stands as the prototype of psoriasiform eruptions. Literally, psoriasiform means "like or in the shape of psoriasis".<sup>[4]</sup> Pinkus and Mehregan<sup>[5]</sup> observed the intermittent release of serum and leukocytes from dilated blood vessels in papillary dermis resulting in focal parakeratosis and thus, the formation of psoriasiform tissue reaction (squirting papillae). Reed and Clark<sup>[7]</sup> propounded the pattern recognition method for the identification of such disorders. Subsequently, Ackerman<sup>[8]</sup> and Mihm<sup>[9]</sup> modified

**How to cite this article:** Sehgal VN, Dogra S, Srivastava G, Aggarwal AK. Psoriasiform dermatoses. Indian J Dermatol Venereol Leprol 2008;74:94-9.

**Received:** August, 2007. **Accepted:** December, 2007. **Source of Support:** Nil. **Conflict of Interest:** Nil.

these criteria to address the pathogenesis/etiology as well as the reaction pattern. Farmer and Hood<sup>[10]</sup> classified such disorders into three broad groups depending on the degree/presence of psoriasiform epidermal hyperplasia. Elder et al.<sup>[11]</sup> improved upon this classification into the broad groups based on the presence of epidermal proliferation as well as on the variations in the types of affected cells.

## CLASSIFICATION

Several classifications are in vogue to incorporate the entities grouped under the aegis of psoriasiform eruptions. Pinkus<sup>[1]</sup> grouped such disorders under two groups: one with a definite presence of suprapapillary exudates and parakeratosis, the other presenting a diagnostic dilemma [Table 1].

Farmer and Hood<sup>[10]</sup> based their classification chiefly on the presence of a characteristic pattern of epidermal hyperplasia [Table 2].

However, Elder et al.<sup>[11]</sup> classified psoriasiform disorders based on the presence of predominant cell type in the infiltrate [Table 3].

## ETIOLOGY

Diverse etiologic agents can be recorded in different instances of psoriasiform eruptions/dermatoses [Table 4].<sup>[12-72]</sup> The 'major psoriasiform dermatoses' are psoriasis, pustular psoriasis, AIDS-associated psoriasiform dermatitis, Reiter's syndrome, pityriasis rubra pilaris, parapsoriasis and lichen simplex chronicus. As a rule, this group of dermatoses is characterized by regular epidermal hyperplasia, although such features are usually absent in the early stages.<sup>[2]</sup>

Newer drugs are still being added to the etiologic list of psoriasiform drug eruptions. Acquired immunodeficiency syndrome has added another dimension to the entity by

producing the psoriasiform eruption *per se* or through other infective disorders, such as leishmaniasis, which affect AIDS patients [Table 4].

## PATHOGENESIS

Although the exact pathogenesis of psoriasiform dermatoses is uncertain, it is believed that the events that precipitate psoriasiform changes are frequently inflammatory. They appear to involve the dysregulation

**Table 2: Farmer and Hood<sup>[10]</sup> classification of psoriasiform dermatitis**

Group-1	Diseases showing psoriasiform epidermal hyperplasia as a characteristic feature a. Psoriasis b. Reiter's disease c. Lichen simplex chronicus d. Pityriasis rubra pilaris e. Pellagra f. Inflammatory liner verrucous epidermal nevus g. Associated with acquired immuno deficiency syndrome (AIDS) h. Acrodermatitis enteropathica i. Necrolytic migratory erythema
Group-2	Diseases showing psoriasiform epidermal hyperplasia as a frequent feature a. Contact dermatitis b. Nummular dermatitis/eczema c. Seborrheic dermatitis d. Psoriasiform syphlids e. Mycosis fungoides f. Pityriasis rosea
Group-3	Diseases showing psoriasiform epidermal hyperplasia as an occasional feature a. Dermatophytoses b. Candidiasis c. Norwegian scabies

**Table 3: Classification of psoriasiform disorders<sup>[11]</sup>**

Types	Example(s)
1. Lymphocyte predominant	a. Nummular dermatitis b. Pityriasis rosea c. Lichen simplex chronicus
2. Plasma cell predominant	a. Psoriasiform syphlids b. Arthropod bite reaction
3. Eosinophils predominant	a. Chronic allergic dermatitis b. Exfoliative dermatitis c. Cutaneous T-cell lymphoma (CTCL)
4. Neutrophils predominant	a. Psoriasis b. Dermatophytoses c. Reiter's disease

**Table 1: Pinkus view of psoriasiform disorders<sup>[1]</sup>**


Group-1	Group-2
Definite: Suprapapillary exudate and parakeratosis	Probable
a. Psoriasis - all presentations	a. Nummular eczema
b. Reiter's syndrome	b. Pityriasis rubra pilaris
c. Acrodermatitis continua	c. Lichen simplex chronicus
d. Impetigo herpetiformis	d. Subcorneal pustular dermatosis
e. Seborrheic dermatitis	e. Folliculitis
f. Asteatotic dermatitis	f. Impetigo
	g. Pustulosis palmo-plantaris

**Table 4: Etiology of psoriasiform eruptions**


Etiology	Disorders
1. Erythematous-scaly	<ul style="list-style-type: none"> <li>• Psoriasis<sup>[1,2]</sup></li> <li>• Disorders of keratinization<sup>[3,13]</sup> <ul style="list-style-type: none"> <li>• Pityriasis rubra pilaris<sup>[13,14]</sup></li> <li>• Erythrokeratoderma<sup>[15]</sup></li> <li>• Papillon-Lefevre syndrome<sup>[16]</sup></li> <li>• Lamellar ichthyosis<sup>[17]</sup></li> </ul> </li> <li>• Reiter's disease<sup>[18]</sup></li> <li>• Pityriasis rosea<sup>[19]</sup></li> <li>• Erythroderma/exfoliative dermatitis<sup>[20]</sup></li> </ul>
2. Eczematous	<ul style="list-style-type: none"> <li>• Seborrhoeic dermatitis<sup>[2]</sup></li> <li>• Nummular dermatitis<sup>[2,5]</sup></li> <li>• Lichen simplex chronicus<sup>[21,22]</sup></li> <li>• Allergic contact dermatitis<sup>[23-25]</sup></li> </ul>
3. Infective	
• Viral	<ul style="list-style-type: none"> <li>• AIDS-associated psoriasiform dermatitis<sup>[26-28]</sup></li> </ul>
• Spirochetal	<ul style="list-style-type: none"> <li>• Psoriasiform syphilids<sup>[29,30]</sup></li> </ul>
• Fungal	<ul style="list-style-type: none"> <li>• Dermatophytes infection<sup>[31,32]</sup></li> </ul>
• Parasitic	<ul style="list-style-type: none"> <li>• Candidiasis<sup>[33]</sup></li> <li>• Leishmaniasis<sup>[34]</sup></li> </ul>
4 Malignant	<ul style="list-style-type: none"> <li>• Norwegian scabies<sup>[35,36]</sup></li> <li>• Mycosis fungoides<sup>[37]</sup></li> <li>• Hodgkin's disease (paraneoplastic)<sup>[38]</sup></li> <li>• Bazex syndrome<sup>[39]</sup></li> </ul>
5. Drug-induced	<ul style="list-style-type: none"> <li>• Anticonvulsant drugs<sup>[52-54]</sup></li> <li>• Fluorescein sodium<sup>[55]</sup></li> <li>• Infliximab<sup>[56]</sup></li> <li>• Icodextrin<sup>[57]</sup></li> <li>• Metformin<sup>[58]</sup></li> <li>• Terbinafine<sup>[59]</sup></li> <li>• Recombinant granulocyte-macrophage colony stimulating factor (rGM-CSF)<sup>[60-61]</sup></li> <li>• Venlafaxine<sup>[62]</sup></li> <li>• Pegylated-liposomal doxorubicin<sup>[63]</sup></li> <li>• Calcium channel blockers<sup>[64]</sup></li> <li>• Botulinum A toxin<sup>[65]</sup></li> <li>• Beta blockers<sup>[66]</sup></li> <li>• Mitomycin<sup>[67]</sup></li> <li>• Captopril<sup>[68]</sup></li> <li>• Chlorthalidone<sup>[68]</sup></li> <li>• Quinidine<sup>[69]</sup></li> <li>• Glibenclamide<sup>[70]</sup></li> <li>• Lithium<sup>[71]</sup></li> <li>• Digoxin<sup>[72]</sup></li> </ul>
6. Other causes	<ul style="list-style-type: none"> <li>• Inflammatory linear verrucous epidermal nevus<sup>[40]</sup></li> <li>• Pellagra<sup>[10]</sup></li> <li>• Necrolytic migratory erythema<sup>[10]</sup></li> <li>• Acrodermatitis enteropathica<sup>[41]</sup></li> <li>• Parapsoriasis<sup>[42]</sup></li> <li>• Kawasaki disease<sup>[43]</sup></li> <li>• Chondro-dysplasia<sup>[44]</sup></li> <li>• Sarcoidosis<sup>[45]</sup></li> <li>• Subacute cutaneous LE<sup>[46]</sup></li> <li>• Acral psoriasiform hemispherical papulosis<sup>[47]</sup></li> <li>• Psoriasiform acral dermatitis<sup>[48]</sup></li> <li>• Psoriasiform and sclerodermoid dermatitis of the fingers<sup>[49]</sup></li> <li>• Infantile febrile psoriasiform dermatitis<sup>[50]</sup></li> <li>• Sulzberger-Garbe exudative discoid and lichenoid dermatitis<sup>[51]</sup></li> </ul>

of cytokines and growth factors which are vital to the maintenance of normal epidermal proliferation.<sup>[2,5,73]</sup> An overexpression of amphiregulin has been shown to induce psoriasiform changes in the skin of transgenic mice shortly after birth.<sup>[74]</sup>


The stages of development of the lesions in psoriasiform dermatitis may contribute to the variable morphologic presentation in different disorders. Murphy<sup>[6,73]</sup> discussed the temporal evolution of psoriasiform dermatitis from the initial stage A, to a fully developed stage, E. Initial stage A shows a subtle basal cell hyperplasia and focal parakeratosis which later slowly evolves into irregular epidermal hyperplasia B, and hypergranulosis and occasional neutrophils in parakeratotic area (stage C). Further evolution leads to a regular epidermal hyperplasia, upward-growing edematous dermal papillae with dilated capillary loops (stages D and E) [Figures 1-3].<sup>[6,73]</sup>



**Figure 1: Subacute spongiform dermatitis- Irregular psoriasiform hyperplasia of epidermis with mild spongiosis and focal parakeratosis with preservation of granular layer**



**Figure 2: Evolving psoriasis showing neutrophilic spongiosis and absence of granular layer (Murphy stage C)**



**Figure 3: Established psoriasis- Regular psoriasiform hyperplasia with elongated mounds of parakeratosis containing occasional neutrophils (Murphy stage D)**

## CLINICAL FEATURES

Psoriasiform lesions appear morphologically similar to the prototypic classical psoriasis. However, depending upon the disorder, the lesions may vary in size, shape, scaling, distribution and configuration<sup>[53]</sup> [Figure 4]. Reiter's syndrome may show classic rupioid/circinate lesions with keratoderma blennorrhagica,<sup>[18,53]</sup> while pityriasis rubra pilaris reveals hyperkeratotic peri-follicular lesions with a halo of erythema.<sup>[13,53]</sup> Similarly, pityriasis rosea may reveal oval plaques with a collarette of fine scaling.<sup>[19]</sup> On the other hand, AIDS-associated psoriasiform lesions may be more "angry"-looking with a prominent component of seborrhoeic dermatitis.<sup>[26-28]</sup> Nummular dermatitis may show only moist and scaly, coin-shaped lesions.<sup>[11]</sup> Drug-induced psoriasiform<sup>[57-72]</sup> and psoriasiform syphlids lesions<sup>[29-30]</sup> may retain their classical pathognomonic signs which can delineate the diagnosis. Further investigations may clinch the exact pathology.<sup>[53]</sup> The list of disorders presenting either as clinical



**Figure 4: Psoriasiform lesions mimic psoriasis**

or as pathological evidence of psoriasiform eruptions is so big that it is not possible to individually discuss features of these disorders. If clinical examination does not provide a clear cut diagnosis, a histopathological investigation will definitely help to make a precise assessment of the dermatosis.<sup>[1,2,5]</sup> Accordingly, other relevant tests such as serological tests for syphilis, provocations tests for drug eruptions etc, can be undertaken according to the merits of the case.<sup>[53]</sup>

## HISTOPATHOLOGY

The clinico-histological correlation of psoriasiform dermatoses is intriguing. A classical histopathological pattern of psoriasiform dermatoses displays a uniform elongation of the rete ridges, papillomatosis and cellular infiltrate both in the epidermis and dermis. Hypergranulosis and parakeratosis may be other accompaniments.<sup>[2,8-10]</sup> Various cutaneous disorders depicting psoriasiform dermatitis may still retain a few features. The histopathology of mycosis fungoides may show a variable degree of epidermotropism with hyperchromatic and hyperconvoluted nuclei in lymphocytes.<sup>[37]</sup> Dermatophytosis shows focal parakeratosis, focal spongiosis and uneven epidermal hyperplasia.<sup>[31-32]</sup> A sandwich sign-presence of fungal elements between the viable epidermis below and the parakeratotic stratum corneum above can be demonstrated in special stains.<sup>[32]</sup> Similarly, crusted scabies<sup>[10,36]</sup> and secondary syphilis<sup>[29]</sup> can be identified due to the presence of the causative mite and spirochete, respectively. However, newer conditions are being continuously added to this group, which depict a subtle variation on the basic theme of the psoriasiform reaction pattern.<sup>[47-50]</sup>

## REFERENCES

1. Pinkus H. Psoriasiform tissue reactions. *Australas J Dermatol* 1965;8:31-5.
2. Weedon D, Strutton G. Psoriasiform tissue reactions. *In: Weedon D, editor. Skin pathology 2<sup>nd</sup> ed. Churchill Livingstone: New York; 2002. p. 76-9.*
3. Barr RJ, Young EM Jr. Psoriasiform and related papulosquamous disorders. *J Cutan Pathol* 1985;12:412-5.
4. Leider M, Rosenblum M, A Dictionary of Dermatologic words terms and phrases. 3<sup>rd</sup> ed. Dome Laboratories: West Haven, Connecticut; 1976. p. 349.
5. Pinkus H, Mehregan AH. The primary histologic lesions of seborrhoeic dermatitis and psoriasis. *J Invest Dermatol* 1966;46:109-16.
6. Maize JC. Dermatitis and epidermal hyperplasia. *In: Maize JC, Burgdorf WH, Hunt ME, et al, editors. Cutaneous pathology. 1<sup>st</sup> ed, Philadelphia: Churchill Livingstone; 1998. p. 169.*
7. Wolf K, Kibbi AG, Mihm MC Jr. Basic Pathologic reactions of the skin. *In: Dermatology in general medicine. Fitzpatrick TB,*

- Eisen AZ, Wolff K, Freedberg IM, Austen KF, editors. New York: McGraw-Hill; 1993. p. 66-86.
8. Ackerman AB. A method of pattern analysis. *In: Histologic diagnosis of inflammatory skin diseases.* Philadelphia: Lea and Febiger; 1978. p. 124-6.
  9. Mihm MC. Psoriasiform dermatitis. *In: Hood AF, Kwan TH, Mihm MC, et al, editors. Primer of Dermatopathology.* Boston: Little Brown; 1993. p. 102-6.
  10. Smotter BR. Psoriasiform dermatitis. *In: Pathology of the skin.* Farmer ER, Hood AF, editors. 1<sup>st</sup> ed. New York: McGraw Hill; 2000. p. 170-4.
  11. Elder D, Rosalie E, Wood ME. Algorithmic classification of skin disease for differential diagnosis. *In: Lever's Histopathology of the skin.* Elder D, editor. 8<sup>th</sup> ed. Philadelphia: Lippincott Williams and Wilkins; 1997. p. 93-4.
  12. Baker H. Psoriasis: A review. *Dermatologica* 1975;180:16-25.
  13. Fox BJ, Odom RB. Papulo-squamous disease: A review. *J Am Acad Dermatol* 1985;12:597-624.
  14. Sehgal VN, Srivastava G. (Juvenile) Pityriasis rubra pilaris. *Int J Dermatol* 2006;45:438-46.
  15. Watanabe K, Hatamochi A, Arakawa M, Ueki H, Nomura S, Osawa G. Congenital psoriasiform erythrokeratoderma with cleidocranial dysplasia, urogenital anomalies and atresia ani. *Dermatology* 1996;192:368-72.
  16. Georgala S, Befon A, Georgala C. Psoriasiform plaques and periodontal infection--quiz case. diagnosis: Papillon-Lefèvre syndrome. *Arch Dermatol* 2005;141:779.
  17. Kahn D, Altman H, Hutchinson E. Lamellar ichthyosis with episodic psoriasiform reaction pattern. *Cutis* 1986;37:162-4.
  18. Perry HO, Mayne JG. Psoriasis and Reiter's syndrome. *Arch Dermatol* 1965;92:129-36.
  19. Parsons JM. Pityriasis rosea: An update. *J Am Acad Dermatol* 1986;15:159-67.
  20. Sehgal VN, Srivastava G, Sardana K. Erythroderma/exfoliative dermatitis: A synopsis. *Int J Dermatol* 2004;43:39-47.
  21. Rowland Payne CM, Wilkinson JD, McKee PH, Jurecka W, Black MM. Nodular prurigo: A clinical pathological study of 46 patients. *Br J Dermatol* 1985;113:431-9.
  22. Ackerman AB. Subtle clues to diagnosis by conventional microscopy--marked compact hyperkeratosis as a sign of persistent rubbing. *Am J Dermatol Pathol* 1980;2:149-52.
  23. Mason KV, Halliwell RE, McDougal BJ. Characterization of lichenoid-psoriasiform dermatosis of springer spaniels. *J Am Vet Med Assoc* 1986;189:897-901.
  24. White WB, Schulman P, McCabe EJ. Psoriasiform cutaneous eruptions induced by cetamolol hydrochloride. *Arch Dermatol* 1986;122:857-8.
  25. Gulbahar O, Ozturk G, Erdem N, Kazandi AC, Kokuludag A. Psoriasiform contact dermatitis in a beekeeper due to propolis. *Ann Allergy Asthma Immunol* 2005;94:509-11.
  26. Puig L, Fernandez, Figueras MT, Ferrándiz C, Ribera M, de Moragas JM. Epidermal expression of 65 and 72 KD heat-shock proteins in psoriasis and AIDS associated psoriasiform dermatitis. *J Am Acad Dermatol* 1995;33:985-9.
  27. Romani J, Puig L, Baselga E, de Moragas JM. Reiter's syndrome-like pattern in AIDS-associated psoriasiform dermatitis. *Int J Dermatol* 1996;35:484-8.
  28. Utikal J, Beck F, Dippel E, Klemke CD, Goerdts S. Reiter's syndrome-like pattern in AIDS-associated psoriasiform dermatitis. *J Eur Acad Dermatol Venereol* 2003;17:114-6.
  29. Abell E, Marks R, Wilson JE. Secondary syphilis: A clinico pathological review. *Br J Dermatol* 1975;95:53-6.
  30. Jeerapaet P, Ackerman AB. Histologic patterns of secondary syphilis. *Arch Dermatol* 1973;107:373-7.
  31. Gianni C, Betti R, Crosti C. Psoriasiform Id reaction in tinea-corporis. *Mycoses* 1996;39:307-8.
  32. Gottlieb CJ, Ackerman AB. The sandwich sign of dermatophytosis. *Am J Dermatol Pathol* 1986;8:347-50.
  33. Krause H, Meinhof W, Spittel E. Are infants and young children with psoriasiform candidosis potential psoriasis patients? *Mykosen* 1984;27:88-94.
  34. Rubio FA, Robayna G, Herranz P, Torres E, Pena JM, Contreras F. Leishmaniasis presenting as a psoriasiform eruption in AIDS. *Br J Dermatol* 1997;136:792-4.
  35. Chan LS. Generalized pruritic psoriasiform lesions. Scabies. *Arch Dermatol* 1991;127:1833-6.
  36. Fernandez, N, Terre A, Ackerman AB. Pathologic findings in human scabies. *Arch Dermatol* 1977;113:320-4.
  37. Zackheim Hs, Koo J, LeBoit PE, McCalmont TH, Bowman PH, Kashani-Sabet M. Psoriasiform mycosis fungoides with fatal outcome after treatment with cyclosporine. *J Am Acad Dermatol* 2002;47:155-7.
  38. Milionis HJ, Elisaf MS. Psoriasiform lesions as paraneoplastic manifestation in Hodgkins disease. *Ann Oncol* 1998;9:449-52.
  39. Wishner AJ, Lynfield Y. Psoriasiform dermatitis in a cachectic man: Acrokeratosis paraneoplastica (Bazex' syndrome). *Arch Dermatol* 1988;124:1852-5.
  40. de Jong E, Rulo HF, van de Kerkhof PC. De Inflammatory linear verrucous epidermal naevus (ILVEN) versus linear psoriasis: A clinical, histological and immunohistochemical study. *Acta Derm Venereol* 1991;71:343-6.
  41. Marko PB, Miljkovic J, Zemljic TG. Necrolytic migratory erythema associated with hyperglucagonemia and neuroendocrine hepatic tumors. *Acta Dermatovenereol Alp Panonica Adriat* 2005;14:161-4.
  42. Sehgal VN, Srivastava G, Aggarwal AK. Parapsoriasis a complex issue. *Skinmed* 2007;6:280-6.
  43. Yoon SY, Oh ST, Lee JY, Cho BK. A plaque type psoriasiform eruption following Kawasaki disease. *Pediatr Dermatol* 2007;24:96-8.
  44. Bruch D, Megahed M, Majewski F, Ruzicka T. Ichthyotic and psoriasiform skin lesions along Blaschko's lines in a woman with X-linked dominant chondrodysplasia punctata. *J Am Acad Dermatol* 1995;33:356-60.
  45. Yanardag H, Pamuk ON, Karayel T. Cutaneous involvement in sarcoidosis: analysis of the features in 170 patients. *Respir Med* 2003;97:978-82.
  46. Frances C, Barete S, Ayoub N, Piette JC. Classification of dermatologic manifestations in lupus erythematosus. *Ann Med Interne (Paris)* 2003;154:33-44.
  47. Ozawa H, Tadaki T, Tagami H. Acral psoriasiform hemispherical papulosis: A new entity? *Dermatology* 1994;189:159-61.
  48. Tosti A, Fanti PA, Morelli R, Bardazzi F. Psoriasiform acral

- dermatitis: Report of three cases. *Acta Derm Venereol* 1992;72:206-7.
49. Caputo R, Gelmetti C, Grimalt R, Gianotti R. Psoriasiform and sclerodermoid dermatitis of the fingers with apparent shortening of the nail plate: a distinct entity?. *Br J Dermatol* 1996;134:126-9.
  50. Tsuge I, Fujii H, Andou Y, Katayama I, Kajita M, Haga Y, *et al.* A case of infantile febrile psoriasiform dermatitis. *Pediatr Dermatol* 1995;12:28-34.
  51. Jansen T, Kupperts U, Plewig G. Sulzberger-Garbe exudative discoid and lichenoid chronic dermatosis ("Oid-Oid disease")-reality or fiction?. *Hautarzt* 1992;43:426-31.
  52. Brenner S, Golan H, Lerman Y. Psoriasiform eruptions and anticonvulsant drugs. *Acta Derm Venereol* 2000;80:382.
  53. Sehgal VN, Srivastava G. Psoriasiform drugs reactions. *In: Treatment of common skin disorders.* Sehgal VN, Srivastava G, editors. 2<sup>nd</sup> ed. India: Jaypee Medical Publishers; 2004. p. 154.
  54. Brenner S, Wolf R, Landau M, Politi Y. Psoriasiform eruptions induced by anticonvulsants. *Isr J Med Sci* 1994;30:283-6.
  55. Mayama M, Hirayama K, Nakano H, Hanada K, Hashimoto I, Tamura M, *et al.* Psoriasiform drug eruption induced by fluorescein sodium used for fluorescein angiography. *Br J Dermatol* 1999;140:982-4.
  56. Takahashi H, Hashimoto Y, Ishida-Yamamoto A, Ashida T, Kohgo Y, Iizuka H. Psoriasiform and pustular eruption induced by infliximab. *J Dermatol* 2007;34:468-72.
  57. Valance A, Lebrun-Vignes B, Descamps V, Queffeuilou G, Crickx B. Icodextrin cutaneous hypersensitivity: Report of 3 psoriasiform cases. *Arch Dermatol* 2001;137:309-10.
  58. Koca R, Altinyazar HC, Yenidunya S, Tekin NS. Psoriasiform drug eruption associated with metformin hydrochloride: A case report. *Dermatol Online J* 2003;9:11.
  59. Papa CA, Miller OF. Pustular psoriasiform eruption with leukocytosis associated with terbinafine. *J Am Acad Dermatol* 1998;39:115-7.
  60. Mossner R, Beckmann I, Hallermann C, Neumann C, Reich K. Granulocyte colony-stimulating-factor-induced psoriasiform dermatitis resembles psoriasis with regard to abnormal cytokine expression and epidermal activation. *Exp Dermatol* 2004;13:340-6.
  61. Cho SG, Park YM, Moon H, Kim KM, Bae SS, Kim GB, *et al.* Psoriasiform eruption triggered by recombinant granulocyte-macrophage colony stimulating factor (rGM-CSF) and exacerbated by granulocyte colony stimulating factor (rG-CSF) in a patient with breast cancer. *J Korean Med Sci* 1998;13:685-8.
  62. Dalle S, Becuwe C, Balme B, Thomas L. Venlafaxine-associated psoriasiform palmoplantar keratoderma and subungual hyperkeratosis. *Br J Dermatol* 2006;154:999-1000.
  63. Kreuter A, Gambichler T, Schlottmann R, Altmeyer P, Brockmeyer N. Psoriasiform pustular eruptions from pegylated-liposomal doxorubicin in AIDS-related Kaposi's sarcoma. *Acta Derm Venereol* 2001;81:224.
  64. Kitamura K, Kanasashi M, Suga C, Saito S, Yoshida S, Ikezawa Z. Cutaneous reactions induced by calcium channel blocker: High frequency of psoriasiform eruptions. *J Dermatol* 1993;20:279-86.
  65. Bowden JB, Rapini RP. Psoriasiform eruption from intramuscular botulinum A toxin. *Cutis* 1992;50:415-6.
  66. Heng MC, Heng MK. Beta-adrenoceptor antagonist-induced psoriasiform eruption: Clinical and pathogenetic aspects. *Int J Dermatol* 1988;27:619-27.
  67. Arrizabalaga M, Casanueva T, Benitez J, Escribano G, Gallardo C. Massive secondary psoriasiform dermatitis secondary to intravesical administration of mitomycin C. *Arch Esp Urol* 1989;42:670-2.
  68. Wolf R, Dorfman B, Krakowski A. Psoriasiform eruption induced by captopril and chlorthalidone. *Cutis* 1987;40:162-4.
  69. Brenner S, Cabili S, Wolf R. Widespread erythematous scaly plaques in an adult. Psoriasiform eruption induced by quinidine. *Arch Dermatol* 1993;129:1331-2.
  70. Goh CL. Psoriasiform drug eruption due to glibenclamide. *Australas J Dermatol* 1987;28:30-2.
  71. Lambert D, Beer F, Gisselman R, Bouilly D, Chapuis JL. Cutaneous lesions due to lithium therapy. *Ann Dermatol Venereol* 1982;109:19-24.
  72. David M, Livni E, Stern E, Feuerman EJ, Grinblatt J. Psoriasiform eruption induced by digoxin: Confirmed by re-exposure. *J Am Acad Dermatol* 1981;5:702-3.
  73. Murphy GF, Herzberg AJ. Psoriasiform dermatitis *In: Dermatopathology,* Murphy GF, Herzberg AJ, editors. Philadelphia: WB Saunders and Co; 1996. p. 49-50.
  74. Bhagavathula N, Nerusu KC, Fisher GJ, Liu G, Thakur AB, Gemmell L, *et al.* Amphiregulin and epidermal hyperplasia. *Am J Pathol* 2005;166:1009-16.